increases to 30 L/min to 120 L/min. Normal quite breathing inspiratory flow is 15 L/min. Venturi nebulizer creates inspiratory flow of 60 L/min. By increasing inspiratory flow demand, it also gives a subjective feeling of satisfaction with an objective decrease in tachypnea and thereby improves saturation. [4] As it is a high-flow delivery device, it creates positive pressure in nasopharynx which could act like positive end expirarory pressure (PEEP) to prevent alveolar collapse at the end of expiration. Hence, it helps improve ventilation and perfusion ratio, minimizing shunting. [5] 
CONCLUSION
In ICU settings, patients are oxygen dependent due to intrinsic lung pathology or because of weakness in respiratory musculature. Many a time, desaturation may lead to suboptimal respiratory care and premature cessation of nebulization. This technique of using Venturi system with nebulization effectively takes care of the desaturation and improves care in ICU.
Sir,
Nebulization is the delivery of saline or drugs in the form of small droplets to the distal lung, which is a common practice in intensive care unit (ICU). [1] It is done with the help of nebulizers which are connected to the inspiratory limb of breathing circuit either in mechanically or spontaneously ventilated patients. Spontaneously breathing patients who are admitted in ICU also need oxygen supplementation. Nebulization in such patients needs attention with careful monitoring of vitals, airway pressure, and oxygen saturation to prevent any desaturation or other adverse events. [2] During conventional nebulization, even with oxygen flow rate of 6-8 L/min, there is a fall in oxygen saturation. In some cases, if not corrected, it may lead to severe hypoxemia and hemodynamic instability. Therefore, we introduce a noble technique using a Venturi to prevent such events. Venturi is considered a high-flow oxygen therapy device. The final assembly with Venturi is shown in Figure 1 . It is connected between the nebulizer and the oxygen source. Different types of Venturi device (color coded) can be used according to the need. The assembly increases the flow, which helps in the delivery of high FiO 2 preventing desaturation.
In literature, there are numerous other advantages of high-flow therapy. Venturi is commonly used in the hospital setting to deliver controlled percentages of oxygen. [3] During acute distress, the ventilatory demand
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Use of Venturi to prevent desaturation during nebulization Acute cardiogenic shock with paclitaxel use in a lung carcinoma patient Sir,
Paclitaxel is a taxane group of anticancer drug, widely used in the treatment of ovarian, breast, lung, and genitourinary carcinomas. In advanced non-small cell lung carcinomas, paclitaxel is indicated at a dose of ≥175 mg/m 2 in combination with a platinum compound. Toxicities of paclitaxel are commonly bone marrow suppression, hypersensitivity reaction, peripheral neuropathy, and rarely cardiac toxicity. Spectrum of cardiotoxicity varies from asymptomatic bradycardia, AV conduction block, bundle branch block, and ventricular arrhythmia to fatal myocardial ischemia. [1] We are highlighting a case of acute cardiogenic shock shortly after paclitaxel infusion in a patient of squamous cell lung carcinoma in the first cycle of chemotherapy, to emphasize the importance of this rare yet serious, life-threatening cardiac adverse event to improve awareness among clinicians.
A 54-year-old male nondiabetic, nonhypertensive, patient was admitted with stage IV squamous cell right lung carcinoma with left hip metastasis. The baseline vitals as blood pressure, pulse rate, hemogram, and blood biochemistry including blood sugar, urea, creatinine, electrolytes, liver, and renal function tests, electrocardiogram (ECG) were within normal range.
The patient was advised chemotherapy regimen of paclitaxel (175 mg/m 2 ) injection followed by carboplatin (AUC-5) injection at a dose of 450mg. Carboplatin maximum dose capping is based on target area under the curve (AUC) using Calvert formula to avoid toxicity due to overdosing. The first cycle was initiated with the requisite premedications (intravenous ondansetron 8 mg; ranitidine 50 mg; and dexamethasone 8 mg). Within 20 min of initiating paclitaxel infusion (260 mg diluted in 300 ml normal saline), the patient developed profuse sweating, feeble pulse and unrecordable blood pressure, cold extremities, and impaired consciousness without chest pain. The patient did not have any features of any hypersensitivity reaction (angioedema, bronchospasm, and urticaria) or any neurological deficits. Paclitaxel infusion was stopped immediately, and cardiopulmonary resuscitation was given. ECG revealed tachycardia with multiple ventricular ectopics [ Figure 1 ]. In order to rule out acute myocardial infarction as the underlying cause, cardiac enzymes were normal, and serial Troponin-T tests were negative. The SpO 2 was 93%, and random blood sugar levels were within the normal range. The patient was treated with vasopressor agents as noradrenaline, dopamine and hydrocortisone, and moist oxygen inhalation. Echocardiography report showed no regional wall motion defect, the left ventricular ejection fraction was 58% with no other significant abnormalities.
He responded well to conservative treatment and was stabilized hemodynamically within the next 36-48 h. The patient had to be discharged as he refused to give consent for any further chemotherapy.
Although some drugs which were used for premedication (ondansetron and ranitidine) may rarely cause cardiac adverse events, the possibility of any interaction with paclitaxel though not documented cannot be ruled out with certainty. Therefore, the diagnosis of paclitaxel-induced acute cardiogenic shock was made based on clinical suspicion, temporal association, absence of other causes, and previous reports of the pharmacological plausibility of paclitaxel and the observed cardiac adverse event. The positive dechallenge information was also noted.
Causality assessment was done by the WHO UMC causality assessment scale shows "probable," by the Naranjo's scale shows "possible" association and Hartwig's adverse drug
